|14th September 2020||Owen B. Wallace||6,350||Exercise of derivative||$7.84||$49,784.00|
|9th September 2020||Rock Ventures Iii, L.P. Third||1,000,000||Other acquisition or disposition||$0.00|
|28th July 2020||Rock Ventures Iii, L.P. Third||875,000||Conversion of derivative||$0.00|
|28th July 2020||Sanofi||81,250||Open or private purchase||$16.00||$1,300,000.00|
|28th July 2020||Rock Ventures Iii, L.P. Third||4,508,333||Conversion of derivative||$0.00|
|28th July 2020||Sanofi||438,875||Conversion of derivative||$0.00|
|28th July 2020||Rock Ventures Iii, L.P. Third||39,216||Conversion of derivative||$0.00|
|24th July 2020||Plc Glaxosmithkline||1,260,504||Open or private purchase||$2.25||$2,836,134.00|
|21st July 2020||Plc Glaxosmithkline||361,111||Open or private purchase||$18.00||$6,499,998.00|
|21st July 2020||Plc Glaxosmithkline||348,469||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015.